Neurontin: Targeted Neuropathic Pain Relief and Seizure Control
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.44 | $34.40 (0%) | 🛒 Add to cart |
| 20 | $2.15 | $68.80 $43.00 (38%) | 🛒 Add to cart |
| 30 | $1.72 | $103.20 $51.60 (50%) | 🛒 Add to cart |
| 60 | $1.00 | $206.40 $60.20 (71%) | 🛒 Add to cart |
| 90 | $0.86 | $309.60 $77.40 (75%) | 🛒 Add to cart |
| 120 | $0.79 | $412.80 $94.60 (77%) | 🛒 Add to cart |
| 180 | $0.67 | $619.20 $120.40 (81%) | 🛒 Add to cart |
| 270 | $0.54 | $928.80 $146.20 (84%) | 🛒 Add to cart |
| 360 | $0.47
Best per pill | $1238.40 $167.70 (86%) | 🛒 Add to cart |
| Product dosage: 300mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.30 | $43.00 (0%) | 🛒 Add to cart |
| 20 | $3.44 | $86.00 $68.80 (20%) | 🛒 Add to cart |
| 30 | $2.87 | $129.00 $86.00 (33%) | 🛒 Add to cart |
| 60 | $2.01 | $258.00 $120.40 (53%) | 🛒 Add to cart |
| 90 | $1.82 | $387.00 $163.40 (58%) | 🛒 Add to cart |
| 120 | $1.58 | $516.00 $189.20 (63%) | 🛒 Add to cart |
| 180 | $1.43 | $774.00 $258.00 (67%) | 🛒 Add to cart |
| 270 | $1.08 | $1161.00 $292.40 (75%) | 🛒 Add to cart |
| 360 | $0.96
Best per pill | $1548.00 $344.00 (78%) | 🛒 Add to cart |
| Product dosage: 400mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.16 | $51.60 (0%) | 🛒 Add to cart |
| 20 | $3.87 | $103.20 $77.40 (25%) | 🛒 Add to cart |
| 30 | $3.15 | $154.80 $94.60 (39%) | 🛒 Add to cart |
| 60 | $2.29 | $309.60 $137.60 (56%) | 🛒 Add to cart |
| 90 | $2.20 | $464.40 $197.80 (57%) | 🛒 Add to cart |
| 120 | $2.01 | $619.20 $240.80 (61%) | 🛒 Add to cart |
| 180 | $1.74 | $928.80 $313.90 (66%) | 🛒 Add to cart |
| 270 | $1.34 | $1393.20 $361.20 (74%) | 🛒 Add to cart |
| 360 | $1.19
Best per pill | $1857.60 $430.00 (77%) | 🛒 Add to cart |
| Product dosage: 600mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.02 | $60.20 (0%) | 🛒 Add to cart |
| 20 | $4.30 | $120.40 $86.00 (29%) | 🛒 Add to cart |
| 30 | $3.44 | $180.60 $103.20 (43%) | 🛒 Add to cart |
| 60 | $2.87 | $361.20 $172.00 (52%) | 🛒 Add to cart |
| 90 | $2.39 | $541.80 $215.00 (60%) | 🛒 Add to cart |
| 120 | $2.29 | $722.40 $275.20 (62%) | 🛒 Add to cart |
| 180 | $2.03 | $1083.60 $365.50 (66%) | 🛒 Add to cart |
| 270 | $1.75 | $1625.40 $473.00 (71%) | 🛒 Add to cart |
| 360 | $1.43
Best per pill | $2167.20 $516.00 (76%) | 🛒 Add to cart |
Neurontin (gabapentin) is a prescription anticonvulsant and neuropathic pain agent indicated for the management of postherpetic neuralgia and as adjunctive therapy in the treatment of partial seizures. Its mechanism of action, while not fully elucidated, is distinct from other antiepileptic drugs, involving binding to the α2δ subunit of voltage-gated calcium channels in the central nervous system. This action is believed to modulate the release of several neurotransmitters, contributing to its efficacy in stabilizing neuronal activity and mitigating neuropathic pain signals. This product card provides a comprehensive overview for healthcare professionals to support informed clinical decision-making.
Features
- Active Pharmaceutical Ingredient: Gabapentin.
- Pharmacologic Class: Anticonvulsant, Analog of the neurotransmitter gamma-aminobutyric acid (GABA).
- Available Formulations: Film-coated tablets (600 mg, 800 mg), Capsules (100 mg, 300 mg, 400 mg), Oral Solution (250 mg/5 mL).
- Proposed Mechanism of Action: Binds to the α2δ-1 and α2δ-2 auxiliary subunits of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters.
- Pharmacokinetics: Nonlinear absorption due to saturable L-amino acid transport system; bioavailability decreases with increasing dose. Not metabolized hepatically; eliminated renally unchanged.
- Half-life: 5 to 7 hours in patients with normal renal function.
Benefits
- Provides effective management of neuropathic pain associated with postherpetic neuralgia, offering an alternative to traditional analgesics.
- Serves as a well-tolerated adjunctive therapy for partial-onset seizures with and without secondary generalization in patients aged 12 and older.
- Exhibits a favorable pharmacokinetic profile with no hepatic metabolism, reducing the risk of metabolic drug-drug interactions.
- Lacks protein binding, minimizing displacement interactions with highly protein-bound drugs like warfarin or phenytoin.
- Offers flexible dosing schedules and multiple formulations to accommodate individual patient needs and titration requirements.
Common use
Neurontin is primarily approved for two key indications. First, it is indicated for the management of postherpetic neuralgia (PHN), the neuropathic pain that follows an acute episode of herpes zoster infection. Its efficacy in this condition is well-established through multiple randomized controlled trials, demonstrating significant pain reduction and improved sleep interference scores compared to placebo. Second, it is approved as adjunctive therapy (add-on treatment) in the treatment of partial seizures in adults and pediatric patients 3 years and older. It is used in combination with other antiepileptic drugs to achieve better seizure control. Furthermore, gabapentin has a well-documented history of off-label use for various other neuropathic pain conditions (e.g., diabetic neuropathy, central neuropathic pain), restless legs syndrome, and certain anxiety disorders, though these uses are not formally approved by the FDA and require careful clinical judgment.
Dosage and direction
Dosage must be individualized based on therapeutic response and patient tolerance. For postherpetic neuralgia, therapy should be initiated at 300 mg on day one, 300 mg twice daily on day two, and 300 mg three times daily on day three. The dose may be titrated up as needed for pain relief to a daily dose of 1800 mg (divided into three daily doses). Doses up to 3600 mg daily have been studied, but no additional benefit was demonstrated, and a higher incidence of adverse reactions was observed.
For epilepsy (adjunctive therapy), in patients 12 years and older, the effective dose is 900 to 1800 mg/day administered in three divided doses. Titration should begin with 300 mg three times daily on day one, and can be increased using 300 mg or 400 mg capsules three times daily up to 1800 mg/day. Dosage in patients with renal impairment must be adjusted based on creatinine clearance (CrCl). For example, in patients with CrCl 30-60 mL/min, the daily dose is 400-1400 mg in 2-3 divided doses. Dosing for pediatric patients and those with more severe renal impairment follows specific guidelines detailed in the full prescribing information. Administration with food is not required, but taking it with food may help mitigate potential gastrointestinal upset. The capsules should be swallowed whole with water. The oral solution should be measured with a calibrated dosing syringe.
Precautions
Patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior. Antiepileptic drugs, including Neurontin, increase the risk of suicidal thoughts and behavior. Abrupt withdrawal of anticonvulsant therapy may precipitate status epilepticus; therefore, gabapentin should be withdrawn gradually over a minimum of one week. Patients should be cautioned about operating complex machinery, including automobiles, until they have gained sufficient experience on Neurontin to gauge whether it adversely affects their mental and/or motor performance. The drug may cause dizziness, somnolence, and other CNS effects. Concomitant use with other CNS depressants (e.g., opioids, benzodiazepines) will increase these effects. There have been reports of respiratory depression when gabapentin is used with opioids, particularly in patients with underlying respiratory conditions. Patients with a history of drug abuse should be closely monitored. Gabapentin use has been associated with angioedema and hypersensitivity reactions.
Contraindications
Neurontin is contraindicated in patients with a known hypersensitivity to gabapentin or any of the inactive ingredients in the formulations. There are no other absolute contraindications.
Possible side effect
The most commonly observed adverse reactions (incidence ≥8% and greater than placebo) associated with Neurontin use are:
- Central Nervous System: Dizziness, somnolence, ataxia, fatigue, nystagmus, tremor, nervousness, dysarthria, amnesia, depression, abnormal thinking, twitching.
- Gastrointestinal System: Nausea, vomiting, dyspepsia, dry mouth, constipation, increased appetite.
- Other: Peripheral edema, blurred vision, diplopia, weight gain, headache, infection, fever. Serious but less common adverse reactions include suicidal behavior and ideation, severe dermatological reactions (including Stevens-Johnson syndrome), angioedema, and myopathy/rhabdomyolysis.
Drug interaction
Gabapentin is not metabolized, does not induce or inhibit hepatic cytochrome P450 enzymes, and is not protein-bound, limiting its potential for pharmacokinetic interactions. However, clinically important pharmacodynamic interactions exist:
- Antacids containing aluminum and magnesium: Reduce the bioavailability of gabapentin by approximately 20%. It is recommended to administer gabapentin at least 2 hours following antacid intake.
- Opioids (e.g., morphine, hydrocodone, oxycodone): Concomitant use increases the risk of profound sedation, respiratory depression, and death. Dose reduction of both drugs may be necessary.
- Alcohol and other CNS Depressants: May potentiate the sedative effects of gabapentin.
- Other Antiepileptic Drugs: No consistent pattern of interactions, though some studies suggest a minor decrease in gabapentin absorption with concomitant phenytoin use.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should be instructed not to take a double dose to make up for a missed one.
Overdose
Overdose has been reported with symptoms including double vision, slurred speech, drowsiness, lethargy, and diarrhea. Fatal cases are rare but have occurred, typically in combination with other drugs (especially opioids) or in patients with renal compromise. Gabapentin can be removed by hemodialysis; this is a recommended course of action in cases of significant overdose, especially in patients with renal failure. Standard supportive measures should be employed, including securing the airway and monitoring vital signs. There is no specific antidote.
Storage
Neurontin capsules and tablets should be stored at room temperature, 20°C to 25°C (68°F to 77°F), in a tightly closed container. The oral solution should be stored in the original container at room temperature or refrigerated (2°C to 8°C / 36°F to 46°F). Do not freeze. Keep all medications out of the reach of children and pets.
Disclaimer
This information is intended for educational purposes and as a summary for healthcare professionals. It is not a substitute for the full Prescribing Information, professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified health provider with any questions you may have regarding a medical condition or before making any changes to a treatment regimen. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- “As a neurologist, I find Neurontin to be a valuable tool in my armamentarium for neuropathic pain. Its predictable pharmacokinetics and lack of significant drug interactions make it easier to incorporate into complex polypharmacy regimens, especially in our elderly population. The titration schedule is generally well-tolerated, though sedation can be a limiting factor initially.” – Neurologist, 15 years experience.
- “From a clinical pharmacy perspective, gabapentin’s renal excretion profile is a double-edged sword. It’s excellent for avoiding hepatic interactions, but it demands vigilant renal dose adjustment in our inpatient population. We see far too many cases of over-sedation and confusion due to inappropriate dosing in patients with acute kidney injury.” – Clinical Pharmacist, Hospital Setting.
- “In my pain management practice, Neurontin is a first-line option for PHN. The evidence base is strong. I appreciate the multiple formulations, which allow me to tailor therapy for patients who have difficulty swallowing pills. The recent boxed warning regarding respiratory depression with concomitant opioids has made us much more cautious in our prescribing and patient education.” – Pain Management Specialist.
- “As an epileptologist, I use gabapentin less frequently as a first-choice adjunctive therapy for epilepsy compared to newer agents, but it remains a viable option, particularly for patients with specific comorbidities or those who are sensitive to drug interactions. Its efficacy is modest but proven.” – Epileptologist.